source
- Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotechJennifer Doudna–founded Scribe Therapeutics intends to use the proceeds from the public offering—the first for a gene editing outfit in over two years—to support development of its epigenetic silen…BioSpace · 5d ago↗ source
- Amgen deploys patients to defend troubled Tavneos in FDA hearing requestFacing pressure around the world to withdraw the rare kidney disease drug Tavneos, Amgen has launched a robust defense with real-world evidence to support the product’s benefit-risk profile.BioSpace · 5d ago↗ source
- STAT+: Fatal gene-editing trial in China raises ethics and oversight questionsSanofi insulin pen in short supply, a win for peptide compounds, and more biotech news from The Readout